| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |